The prognostic value of [<sup>18</sup>F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.

Eur J Nucl Med Mol Imaging · 2023 · PMC10317882 · PMID 37099131

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.1000

boldest claim

The sentences

marginally non-significantp = 0.05actually significant

Further, when patients were dichotomized based on the disease control rate (“DCR”), a significantly longer OS was exhibited in the disease control compared to no-disease control group according to PERCIST (p = 0.01), PERCIMT (p = 0.01) and iPERCIST (p = 0.01), while a similar, marginally non-significant trend was also observed after application of EORTC (p = 0.05).

also in 274 other papers

showed a trendp < 0.1so close (0.05 < p ≤ 0.1)

At that time point, metabolic responders according to the RR dichotomization showed a trend for longer survival according to the conventional PET criteria (EORTC, PERCIST; p < 0.1), which, moreover, was statistically significant with the immunotherapy-modified PERCIMT and imPERCIST5 ( p < 0.05).

also in 13,339 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.